Abstract. In man, serum concentrations of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) decrease with age after the twenties. For this reason, the decline in DHEA and DHEAS concentrations may be related to the development of some chronic diseases that are prevalent in the older age population. In this study, we evaluate the benefit and safety level of DHEA administration to men as a hormone replacement therapy. Twenty-two healthy Japanese males (age 26-63; mean ± SD, 41.0 ± 10.0 yrs.) received 25 mg DHEA once a day orally in the morning for two weeks. Serum concentrations of steroid hormones and cytokines were measured before and after the DHEA administration. Glucose tolerance and insulin resistance were also assessed before and after the DHEA administration using a 75 g oral glucose tolerance test and homeostasis model assessment (HOMA-R), respectively. Serum DHEA and DHEAS levels were significantly elevated after the DHEA administration for all ages of test subjects. In subjects who were older than 41 yrs. (older group) serum androstenedione and estradiol levels were elevated after the DHEA administration. Significant negative correlations were observed between the serum DHEA concentration and the serum concentration of fasting insulin, HOMA-R, leptin, and high-sensitivity C-reactive protein for all subjects. Daily administration of 25 mg DHEA increased the serum DHEA, DHEAS, androstenedione, and estradiol levels of the subjects of the older group to the same level as that of younger subjects. WHILE it is known that there is an abundance of dehydroepiandrosterone (DHEA) and its sulfate conjugate (DHEAS) in the peripheral circulation in humans, their essential physiological roles still remain unclear. It is known that the secretion of DHEA increases with postnatal aging peaking in the twenties, and then decreases with age afterwards. Due to this type of dynamic change, the decline in DHEA and DHEAS secretion based on aging is compared to female menopause and expressed as adrenopause. The relationship of DHEA and DHEAS to symptoms of senility and geriatric disease has attracted much attention [1] . The re-
WHILE it is known that there is an abundance of dehydroepiandrosterone (DHEA) and its sulfate conjugate (DHEAS) in the peripheral circulation in humans, their essential physiological roles still remain unclear. It is known that the secretion of DHEA increases with postnatal aging peaking in the twenties, and then decreases with age afterwards. Due to this type of dynamic change, the decline in DHEA and DHEAS secretion based on aging is compared to female menopause and expressed as adrenopause. The relationship of DHEA and DHEAS to symptoms of senility and geriatric disease has attracted much attention [1] . The re-port by Roth [2] shows that the lifespan of a person and the serum concentration of DHEA are related. There are also reports related to antiatherosclerotic [3] [4] [5] [6] , antidiabetic [7] [8] [9] , antiinflammatory [10] [11] [12] , and antiosteoporotic functions [13, 14] , and we anticipate that DHEA has the so-called antisenility hormone function related to the aging phenomenon.
Hormone replacement therapy is a method for preventing or treating various chronic diseases associated with aging by replacing sex steroid hormones the levels of which decrease due to aging. In aging societies of various advanced countries, concern is on the rise regarding hormone replacement therapy. Although there are many studies underway on estrogen replacement therapy for postmenopausal women [15] [16] [17] [18] , the number of such studies on male hormone replacement therapy is not at the same level. In particular, there are only a few studies on the Japanese population [19, 20] . We conducted an investigation on a short-term and lowdose replacement therapy with DHEA on Japanese men and studied the influence on hormone dynamics, glucose tolerance, and insulin resistance.
Materials and Methods

Test subjects
Twenty-two normal healthy Japanese males (age 26-63; mean ± SD, 41.0 ± 10.0 yrs.) volunteered to be test subjects. Baseline characteristics of the 22 subjects are outlined in Table 1 .
Test design
An open-label test format was used. All subjects received 25 mg DHEA once a day orally in the morning for two weeks. The DHEA is a product of Advanced Brain Research Foundation, Inc. (Cambridge, MA) and was purchased from Gloria International Inc. (Tokyo, Japan). Blood sampling and a 75 g oral glucose tolerance test (75 g OGTT) were performed after 12 h of fasting on the day before and then after two weeks of the DHEA administration. Approval for this study was obtained from the Yokohama City University Hospital Ethical Committee.
Measurement
Serum DHEA, DHEAS, androstenedione, estradiol (E2), and free testosterone were measured using the solid phase radioimmunoassay (Diagnostic Products Corporation, CA, USA). Serum IGF-1 was measured using the solid phase radioimmunoassay (Daiichi Radioisotope Corporation, Tokyo, Japan). All of these measurements and complete blood count, liver function, renal function, electrolytes, lipids, glucose, and insulin measurements were performed in commercial laboratories (SRL, Inc., Tokyo, Japan). Evaluation of insulin resistance was assessed with homeostasis model assessment (HOMA-R) and calculated using the following formula: fasting plasma glucose (mmol/L) × fasting serum insulin (micro U/mL) divided by 25 [21] . We calculated the insulinogenic index, as the initial insulin secretion response index after glucose tolerance, using a previously described method [22, 23] .
The serum concentration of leptin, adiponectin, and high-sensitivity C-reactive protein (hsCRP) was measured by radioimmunoassay (Cosmic Corporation, Tokyo, Japan), ELISA (Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan), and nephelometry (Dade Behring Inc., IL, USA), respectively. The plasma concentration of soluble intercellular adhesion molecule-1 (ICAM-1), soluble vascular cell adhesion molecule-1 (VCAM-1), and tumor necrosis factor alpha (TNF alpha) was measured by EIA (Bender Medsystems, Vienna, Austria), EIA (R&D Systems Inc., MN, USA), and ELISA (Japan Immunoresearch Laboratories Co. Ltd., Gunma, Japan), respectively.
Statistical analysis
Statistical analysis was performed using StatView 5.0 for Windows ® . Paired t test, two-sample t independent-group test, the Wilcoxon signed-rank test, and the Mann Whitney U test were used to compare each of the measured values of the basic level before the administration of DHEA and that after two weeks of administration. The Spearman ranking correlation coefficient was used to verify the correlation coefficient. A P value <0.05 was considered statistically significant.
Results
Change in hormone concentration in blood Table 2 gives the hormone concentration before and after the DHEA administration. After administration of 25 mg DHEA for two weeks, the serum concentration of DHEA, DHEAS, and androstenedione exhibited a significant increase; however, IGF-1, E2, and testosterone showed no significant change. Because the basal level of the serum DHEA and DHEAS concentration decreases with age, subjects were divided into two groups according to their age. The subjects who were ≤41 years of age were classified into the younger group, and those >41 years of age were classified into the older group. In the younger group, after two week administration of 25 mg DHEA, the serum concentration of DHEA and DHEAS exhibited a significant increase. In the older group, after two week administration of 25 mg DHEA, in addition to DHEA and DHEAS, the concentration of androstenedione and E2 exhibited a significant increase. For comparison of dosage effectiveness, we tested the administration of 50 mg DHEA as a preliminary study. Table 2 also gives the hormone concentration after the 50 mg DHEA administration. There were no differences in any of the hormone concentrations between the 25 mg and 50 mg DHEA administration. When investigating the correlation between age and each serum hormone concentration before and after the DHEA administration, serum DHEAS and E2 were found to decrease significantly with age. After the administration of 25 mg DHEA for two weeks, such age related decrease in DHEAS and E2 disappeared. Although there was a tendency for the serum concentration of DHEA and androstenedione to decrease with age, it was not statistically significant (Fig. 1) . The serum hormone concentration of the older group was shown to increase to the same level as that of younger group for DHEA, DHEAS, androstenedione, and E2.
Effect on routine examination
After the administration of 25 mg DHEA for two weeks, there was no significant change in the complete blood count, liver function, renal function, electrolyte, or uric acid value (data not shown). In regard to the effect on lipids, there was no significant change in the Values are expressed as the mean ± S.D. total cholesterol, LDL cholesterol, HDL cholesterol, or triglyceride concentration as indicated in Table 3 .
Effect on glucose metabolism
After the administration of 25 mg DHEA for two weeks, there was no significant change in the fasting plasma glucose and fasting serum insulin level. During 75 g OGTT, there were no significant changes in the two-hour plasma glucose level, HOMA-R, or insulinogenic index. However, when comparing the relationship between each evaluation item and the DHEA concentration, regardless of before or after administration, we recognized a significant negative correlation between the serum DHEA concentration and the fasting insulin concentration or the HOMA-R (Fig. 2) . This finding indicates that the lower the blood DHEA level became, the higher the insulin resistance. In 19 subjects, HOMA-R was calculated before and after the two week administration of DHEA. There were nine subjects whose serum concentration of DHEA was elevated to higher than 21.1 nmol/l, which was the same as the mean concentration of the younger subjects. When a change in serum concentration of DHEA was compared to that for HOMA-R in each subject, three subjects with marked insulin resistance whose HOMA-R level was higher than 2.0 showed a decline in the HOMA-R level after 25 mg of DHEA administration as shown in Fig. 3 . No constant tendency was observed in six normal insulin sensitivity subjects whose HOMA-R level was lower than 2.0. These findings suggest the possibility that when the serum concentration of DHEA exceeds a certain level as a result of hormone replacement therapy, insulin resistance reverts to normal (Fig. 3) .
Correlation of serum DHEA concentration to cytokines and adhesion molecules (Before and after DHEA administration) The relationship of the DHEA level to cytokines and adhesion molecules, which are thought to have a relationship with insulin resistance and atherosclerosis, were studied by determining leptin, adiponectin, hsCRP, TNF alpha, soluble ICAM-1, and soluble VCAM-1. There was a significant negative correlation between the serum DHEA concentration and the serum concentration of leptin and hsCRP as shown in Fig. 4 . Furthermore, leptin exhibited a significant positive correlation with insulin, HOMA-R, and hsCRP, and a negative correlation with adiponectin as indicated in Fig. 5 . Fig. 3 . Changes in HOMA-R among subjects whose serum DHEA level was elevated
In subjects with a HOMA-R higher than two, there is a clear decrease in the HOMA-R level after the two week DHEA administration.
Discussion
It is well known that the concentration of the male sex hormone decreases gradually with age, and discussion regarding the usefulness of hormone replacement therapy is becoming widespread [24] [25] [26] . Maintaining health and preventing chronic diseases in an aging society are important issues facing advanced countries, and DHEA replacement therapy is anticipated to be a possible solution to these problems. In this study, not only DHEA or DHEAS, but also androstenedione and E2 exhibited a tendency to decrease with age, and through the 25 mg per day DHEA administration the decreased levels of these hormone concentrations recovered to the same level as that of the younger subjects. In reports up to now, there have been many examples of replacement studies using doses greater than 50 mg per day [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . However, in this study, we selected 25 mg per day of DHEA administration because the standard dose of many clinically available medicines for Western people tends to be equivalent to the maximum dose for Japanese. It is thought that the administration of a low dose of DHEA might be safer. According to the change in older group's hormone profiles, it is thought that even a 25 mg replacement regimen could be sufficient to obtain an increase in Japanese subjects. Further evaluation regarding the dose effectiveness is required.
In young subjects who exhibited a sufficiently high serum concentration of DHEA before the treatment, no significant change was observed after the 25 mg daily DHEA administration. This might be due to the extensive peripheral metabolism of the orally administered DHEA to other androgens and conjugates [37] . Together with the fact that there were no abnormal values from the blood test or biochemical examination, the above results support the notion that DHEA replacement therapy is safe [38] . However, since the administration was limited to a short two weeks in this study, future investigations are needed involving a low-dose long-term therapy and evaluation of the sex steroid hormone concentration in the blood and the side effects.
DHEA administration was reported to reduce visceral fat and to improve insulin resistance [39] . In the results of the 75 g OGTT administered this time, while there was no discernable influence on the plasma glucose level, we recognized the negative correlation between the serum DHEA concentration and the fasting insulin level or the HOMA-R. This is consistent with the previous report by Villareal and Holloszy [39] .
In this investigation, we recognized that the serum DHEA concentration and the serum leptin concentration have a negative correlation, and this supports the results reported by Callies et al. [30] . The significant positive correlation between the serum concentration of leptin and the insulin resistance were consistent with the findings of Segal et al. [40] . The relationship between the serum DHEA concentration and the onset frequency of myocardial infarction was identified in previous reports [6, 41] . The results of the current study indicating that there is a negative correlation between the serum DHEA concentration and hsCRP is consistent with the results reported by Leal et al. [42] . According to these results, the serum concentration of DHEA and various factors that are involved in insulin resistance might influence each other [43] . However, the mechanism for the correlation is not clear and further investigation is needed.
In conclusion, the results of this short-term low-dose DHEA administration regimen suggest that supplemental DHEA administration to healthy middle-aged and elderly male subjects may help maintain their serum sex steroid hormone concentration at a younger age level without appreciable side effects. The low dosage of DHEA replacement therapy is expected to have the effect of improving insulin resistance.
